Bristol-Myers Gets FDA Priority Review for Children’s Bipolar Treatment

Bristol-Myers Squibb Co. and partner Otsuka Pharmaceutical Co. Thursday said the Food and Drug Administration has granted a priority review of the supplemental new drug application for atypical anti-psychotic drug Abilify for the treatment of pediatric patients with bipolar I disorder, manic or mixed episodes with or without psychotic features.
ABCmoney.co.uk